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Dear Editor,
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant systemic disorder of angiogenesis characterized by vascular malformations 
in mucocutaneous tissues, visceral organs, and the central nervous system (1). HHT-related neurological deficits and stroke are observed in 15% of 
patients and generally occur as a result of a right-to-left shunt induced by pulmonary arteriovenous malformation (PAVM). In patients in whom PAVM 
and patent foramen ovale (PFO) coexist, both conditions may be responsible for paradoxical embolism. Furthermore, the coexistence of HHT and/
or PFO with inherited hypercoagulable states may identify subjects at higher risk for paradoxical embolism. The coexistence of the three disorders 
leading to stroke via paradoxical embolism is quite rare and gives important information regarding hereditary predisposition.
A 19-year-old female patient who had experienced two previous attacks within the last 3 years was admitted to the neurology department with 
complaints of double vision, right-sided numbness, and gait disturbance. Cranial magnetic resonance imaging showed an acute ischemic lesion 
in the left thalamus. Transesophageal echocardiography showed a Chiari network and PFO. Coagulation test revealed antithrombin III (AT III) 
deficiency [repeated twice at different times, result: 68 (80–120)]. After treatment with acetylsalicylic acid, the patient experienced an episode of 
epistaxis. Her nasal examination revealed nasal telangiectasias. Her history revealed that her mother and grandfather also had frequent episodes 
of epistaxis and telangiectasia on the lips. Thoracic and USAominal computed tomography demonstrated multiple pulmonary and hepatic arte-
riovenous malformations. On genetic investigation, an unknown heterozygous mutation from T to C at the c.88T>C position of the ENG gene 
was detected. We performed no genetic examination related to AT III deficiency. HHT and thrombophilia are rarely seen concomitantly as two 
genetic disorders that exhibit theoretically opposite actions on hemostasis (2,3,4). The genetic heterogeneity of HHT may lead to its coexistence 
with different genetic disorders. Recent studies suggested that prothrombotic mutations are genetic risk factors for cryptogenic ischemic stroke 
in young adults (5,6), and a relationship between prothrombotic mutations and a risk for cerebral ischemia is present in younger PFO patients 
(7,8,9). Other reports also state an association between PFO-related cerebral infarction and inherited thrombophilia (7,10,11,12). In fact, genetic 
thrombophilic defects may affect the potential risks and reduce the expected benefits of percutaneous PFO closure (10). Data by Botto indicate 
that the coexistence of PFO and inherited hypercoagulable states may identify individuals at higher risk for paradoxical embolism (10). Such condi-
tions give rise to a difficult management problem when they occur concomitantly in one patient. On the other hand, for the clinical management 
of these patients, performing genetic testing and counseling for inherited thrombophilia may be useful to prevent vascular complications and use 
better pharmacological modalities, in consideration of the possible presence of both genetic conditions (13). Informed consent was obtained from 
patients and we consider that the coexistence of these three disorders may not be a coincidence, but may have arisen from a novel ENG mutation. 
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